Analysts who follow Immunitybio Inc (IBRX) on average expect it to decline -26.71% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns Immunitybio Inc an Analyst Ranking of 36, which means it ranks higher than 36 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating IBRX a Buy today. Find out what this means to you and get the rest of the rankings on IBRX!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Immunitybio Inc Stock Today?
Immunitybio Inc (IBRX) stock is trading at $6.14 as of 10:47 AM on Thursday, Mar 21, a rise of $0.15, or 2.5% from the previous closing price of $5.99. The stock has traded between $5.68 and $6.27 so far today. Volume today is less active than usual. So far 1,256,560 shares have traded compared to average volume of 4,430,064 shares.
Click Here to get the full Stock Report for Immunitybio Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
